Hardman Report: New frontiers in T-cell activation

RNS Number : 7395K

Scancell Holdings Plc

26 September 2016

 

Hardman Research: New frontiers in T-cell activation

New frontiers in T-cell activation and targeting: Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates high avidity anti-tumour T-cells for use as a monotherapy or in combination with checkpoint inhibitors. Moditope targets modified antigens and stimulates powerful anti-tumour T-cell responses for use in advanced and hard-to-treat cancers. Both platforms are targeting multi-billion dollar markets. The recent capital increase will be used to advance both platforms to the next stage of development and investment in corporate infrastructure.   

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/scancell-documents/26.09.16-new-frontiers-in-t-cell-activation-and-targeting.pdf

To contact us:    Hardman & Co 11/12 Tokenhouse Yard  London EC2R 7AS

Contact: Dr Martin Hall [e-mail]  Dr Dorothea Hill [e-mail] Dr Gregoire Pave [e-mail] Telephone: [phone] Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

END

 

 

NRASEEFIDFMSEIU